UBS lowered the firm’s price target on Aemetis (AMTX) to $2.50 from $6.75 and keeps a Buy rating on the shares. The firm reduced estimates to reflect renewable identification numbers uncertainty, the company’s Q4 earnings miss, and low carbon fuel standard outlook. UBS views RIN pricing for 2025 as remaining unclear due to potential regulatory changes
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMTX:
- Aemetis announces production of RNG increased 55% in March vs February
- Aemetis Reports Strong Revenue Growth Amid Challenges
- Aemetis Inc’s Earnings Call: Growth Amid Challenges
- Aemetis Positioned for Growth with Renewable Natural Gas Expansion and Biodiesel IPO Prospects
- Is AMTX a Buy, Before Earnings?